John N. Allan

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Erik Volz, Verity Hill, John T. McCrone et al. · Cell · 2020 · 1.1K citations · Full text

Life Sciences, Genetics, Infectious Diseases +17

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna et al. · Blood · 2020 · 318 citations · Full text

Pharmacy, Health Sciences, Internal Medicine +3

Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia

Federico Gaiti, Ronan Chaligné, Hongcang Gu et al. · Nature · 2019 · 271 citations · Full text

Life Sciences, Biology, Molecular Biology +16

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Constantine S. Tam, John N. Allan, Tanya Siddiqi et al. · Blood · 2022 · 238 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

William G. Wierda, John N. Allan, Tanya Siddiqi et al. · Journal of Clinical Oncology · 2021 · 229 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14